SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.            )*

ARCA biopharma, Inc.

(Name of Issuer)

(Title of Class of Securities)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	o		Rule 13d-1(b)
	þ		Rule 13d-1(c)
	o		Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No.		00211Y 10 0	13G	Page		2		of		13 Pages

(1)  This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		3		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		4		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		5		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		6		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		7		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		8		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

CUSIP No.		00211Y 10 0	13G	Page		9		of		13 Pages

(1) This Schedule 13G is filed by Boulder Ventures IV (Annex), L.P. (“BV IV Annex”), Boulder Ventures IV, L.P. (“BV IV LP”), BV Partners IV, L.L.C. (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”) (collectively, the “Fund Entities”). The Fund Entities expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2) Includes 725,111 shares of Common Stock and currently exercisable warrants to purchase 28,651 shares of Common Stock held by BV IV Annex and 48,007 shares of Common Stock and currently exercisable warrants to purchase 1,897 shares of Common Stock held by BV IV LP. BV IV LLC serves as the general partner of BV IV Annex and BV IV LP, and owns no securities of the Issuer directly. Fidler, Jones, Lefkoff, Macks and Roshko are Managing Members of BV IV LLC and share voting and dispositive power over the shares held by BV IV Annex and BV IV LP. The information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009.

(3) This percentage is calculated based upon 7,556,786 shares of the Issuer’s common stock outstanding as of February 4, 2009.

Introductory Note: This Statement on Schedule 13G is filed on behalf of Boulder Ventures IV (Annex), L.P., a Delaware limited partnership (“BV IV Annex), Boulder Ventures IV, L.P., a Delaware limited partnership (“BV IV LP”), BV Partners IV, L.L.C., a Delaware limited liability company (“BV IV LLC”), Josh E. Fidler (“Fidler”), Andrew E. Jones (“Jones”), Kyle Lefkoff (“Lefkoff”), Lawrence M. Macks (“Macks”) and Peter Roshko (“Roshko”), in respect of shares of Common Stock of ARCA biopharma, Inc.

Item 1

Item 1(a).		Name of Issuer: ARCA biopharma, Inc. (ABIO)

Item 1(b).		Address of Issuer’s Principal Executive Offices: 8001 Arista Place, Suite 200 Broomfield Co 80021

Item 2(a).		Name of Person(s) Filing: Boulder Ventures IV (Annex), L.P. (“BV IV Annex”) Boulder Ventures IV, L.P. (“BV IV LP”) BV Partners IV, L.L.C. (“BV IV LLC”) Josh E. Fidler (“Fidler”) Andrew E. Jones (“Jones”) Kyle Lefkoff (“Lefkoff”) Lawrence M. Macks (“Macks”) Peter Roshko (“Roshko”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: 1900 Ninth Street, Suite 200 Boulder, CO 80302

Item 2(c).		Citizenship:

		Entities:		BV IV Annex BV IV LP BV IV LLC		— — —		Delaware Delaware Delaware
		Individuals:		Fidler Jones Lefkoff Macks Roshko		— — — — —		United States of America United States of America United States of America United States of America United States of America

Item 2(d).		Title of Class of Securities:                         Common Stock

Item 2(e).		CUSIP Number: 00211Y 10 0

Item 3.		Not applicable.

Item 4.		Ownership

The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13G is provided as of January 27, 2009:

		Shares				Sole				Shared				Sole				Shared
		Held				Voting				Voting				Dispositive				Dispositive				Beneficial				Percentage
Fund Entities		Directly				Power				Power				Power				Power				Ownership				of Class (1)
Boulder IV Annex			752,762	(2)			0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
BV IV LP			49,904	(2)			0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
BV IV LLC (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
Fidler (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
Jones (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
Lefkoff (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
Lawrence (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%
Roshko (3)			0				0				803,666	(2)			0				803,666	(2)			803,666	(2)			10.6	%

Item 5.		Ownership of 5 Percent or Less of a Class

		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.

Item 6.		Ownership of More than 5 Percent on Behalf of Another Person

		Not applicable.

Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

		Not applicable.

Item 8.		Identification and Classification of Members of the Group

		Not applicable.

Item 9.		Notice of Dissolution of a Group

		Not applicable.

Item 10.		Certification

		By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 05, 2009

BOULDER VENTURES IV (ANNEX), L.P.
By:		BV Partners IV, L.L.C.
Its:		General Partner
By:		/s/ Kyle Lefkoff        Kyle Lefkoff, Managing Member
BOULDER VENTURES IV, L.P.
By:		BV Partners IV, LLC
Its:		General Partner
By:		/s/ Kyle Lefkoff        Kyle Lefkoff, Managing Member
BV PARTNERS IV, LLC
By:		/s/ Kyle Lefkoff        Kyle Lefkoff, Managing Member
/s/ Josh E. Fidler
Josh E. Fidler
/s/	Andrew E. Jones
Andrew E. Jones
/s/	Kyle Lefkoff
Kyle Lefkoff
/s/	Lawrence M. Macks
Lawrence M. Macks
/s/	Peter Roshko
Peter Roshko

Exhibit(s):

A — Joint Filing Statement

EXHIBIT A

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of ARCA biopharma, Inc. is filed on behalf of each of us.

Dated: February 05, 2009

BOULDER VENTURES IV (ANNEX), L.P.
By:		BV Partners IV, L.L.C.
Its:		General Partner
By:		/s/ Kyle Lefkoff
		Kyle Lefkoff, Managing Member
BOULDER VENTURES IV, L.P.
By:		BV Partners IV, LLC
Its:		General Partner
By:		/s/ Kyle Lefkoff
		Kyle Lefkoff, Managing Member
BV PARTNERS IV, LLC
By:		/s/ Kyle Lefkoff
		Kyle Lefkoff, Managing Member
/s/	Josh E. Fidler
Josh E. Fidler
/s/	Andrew E. Jones
Andrew E. Jones
/s/	Kyle Lefkoff
Kyle Lefkoff
/s/	Lawrence M. Macks
Lawrence M. Macks
/s/	Peter Roshko
Peter Roshko